title: [Rapaglinide: Novonorm, an alternative in type 2 diabetes].
authors.affiliation: Service de Médecine B, Centre Hospitalier Universitaire d'Angers. BeBouhanick@chu-angers.fr
authors.forename: B
authors.initials: B
authors.lastname: Bouhanick
authors.forename: S S
authors.initials: SS
authors.lastname: Barbosa
mesh_terms: D002219:Carbamates / Q000009:adverse effects / Q000627:therapeutic use*; D000075202:Contraindications; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004347:Drug Interactions; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D013237:Stereoisomerism
chemical_list: D002219:Carbamates; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D010880:Piperidines; C072379:repaglinide
vernacular_title: Repaglinide: Novonorm, une alternative chez le diabétique de type 2.